文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

阿基仑赛用于高危大B细胞淋巴瘤一线治疗的2期ZUMA-12试验

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.
PubMed 文献 · Nat Med · 2022-03-21

ZUMA-12是一项2期、多中心、单臂研究,评估阿基仑赛(axi-cel)作为40例高危大B细胞淋巴瘤一线治疗的一部分。可评估疗效的37例中完全缓解率78%(95%CI 62-90),客观缓解率89%(95%CI 75-97);截至2021年5月17日(中位随访15.9个月),73%的患者维持客观缓解,中位缓解持续时间、无事件生存期和无进展生存期均未达到。

要点

  • 可评估疗效的37例中,完全缓解率78%(95%CI 62-90),客观缓解率89%(95%CI 75-97)。
  • 截至2021年5月17日(中位随访15.9个月),73%的患者维持客观缓解。
  • ≥3级细胞因子释放综合征发生于3例(8%),≥3级神经系统事件发生于9例(23%)。

核心结论

  • 阿基仑赛作为高危大B细胞淋巴瘤一线治疗的一部分高度有效,安全性可控。

研究设计与样本

  • 2期、多中心、单臂ZUMA-12研究(ClinicalTrials.gov NCT03761056),纳入40例高危大B细胞淋巴瘤患者,评估阿基仑赛作为一线治疗的一部分,该试验已完成入组。

主要发现

  • 可评估疗效的37例中,完全缓解率78%(95%CI 62-90),客观缓解率89%(95%CI 75-97)。
  • 截至2021年5月17日(中位随访15.9个月),73%的患者维持客观缓解;中位缓解持续时间、无事件生存期和无进展生存期均未达到。
  • ≥3级细胞因子释放综合征发生于3例(8%),≥3级神经系统事件发生于9例(23%);无治疗相关5级事件。
  • 所有患者均出现稳健的CAR T细胞扩增,中位达峰时间为8天。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High-risk large B-cell lymphoma (LBCL) has poor outcomes with standard first-line chemoimmunotherapy. In the phase 2, multicenter, single-arm ZUMA-12 study (ClinicalTrials.gov NCT03761056) we evaluated axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, as part of first-line treatment in 40 patients with high-risk LBCL. This trial has completed accrual. The primary outcome was complete response rate (CRR). Secondary outcomes were objective response rate (ORR), duration of response (DOR), event-free survival (EFS), progression-free survival (PFS), overall survival (OS), assessment of safety, central nervous system (CNS) relapse and blood levels of CAR T cells and cytokines. The primary endpoint in efficacy-evaluable patients (n = 37) was met, with 78% CRR (95% confidence interval (CI), 62-90) and 89% ORR (95% CI, 75-97). As of 17 May 2021 (median follow-up, 15.9 months), 73% of patients remained in objective response; median DOR, EFS and PFS were not reached. Grade ≥3 cytokine release syndrome (CRS) and neurologic events occurred in three patients (8%) and nine patients (23%), respectively. There were no treatment-related grade 5 events. Robust CAR T-cell expansion occurred in all patients with a median time to peak of 8 days. We conclude that axi-cel is highly effective as part of first-line therapy for high-risk LBCL, with a manageable safety profile.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Neelapu SS, Dickinson M, Munoz J, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022. PMID: 35314842. doi:10.1038/s41591-022-01731-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。